Thursday, July 3, 2025 7/3/2025

A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma

Award Number: R01NS112482
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2019
PERIOD OF PERFORMANCE END DATE: 03/31/2024

Group Awards By:

View Award Description

A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma - Project Summary/Abstract The existence of glioblastoma cancer stem cells (GBM CSCs), as well as the causative role that they play in GBM tumor initiation and disease progression, has been clearly demonstrated and characterized. However, agents that selectively target this cell population and knowledge surrounding potential therapeutic targets are desperately lacking. GBM represents the most common and aggressive form of brain cancer and, at present, remains a virtually incurable disease. Tumor maintenance, brain infiltration, therapy resistance and recurrence following surgery are all attributed to GBM CSC populations. The long-term goal of this project is to identify new targets, mechanisms and potential drug candidates for the treatment of GBM, which function to induce apoptosis in GBM CSCs in a cell type-selective manner. From a completed chemical genetics-based screen of ~1 million drug-like small molecules, a novel compound series, exemplified by a compound termed RIPGBM, was identified that was found to induce apoptosis in GBM CSCs with unparalleled selectivity, based on the profiling of a broad panel of GBM CSCs and non-diseased cell types. The selectivity of this series was determined to be derived from selective activation of RIPGBM in GBM CSCs, which leads to the formation of a species that induces apoptosis by binding to a novel protein target – RIPK2. The overall objectives of this proposal are to fully elucidate the mechanism of action of the RIPGBM compound series, to optimize its selectivity and potency properties and to demonstrate anti-tumor activity in a relevant rodent GBM tumor model. The central hypothesis driving this proposal is that RIPK2-targeting small molecule prodrugs, which become selectively activated in GBM CSCs, induce apoptosis in a cell type-selective manner and reduce tumor burden in GBM tumor models. To achieve the overall objective of this proposal, the following three specific aims will be successfully completed: 1A) Determine the mechanism of selective RIPGBM prodrug activation in GBM CSCs. 1B) Determine the structural basis by which the interaction of cRIPGBM with RIPK2 induces apoptosis. 2) Identify brain penetrant analogs of RIPGBM with improved potency and selectivity properties. 3) Determine the disease modifying activity of an optimal RIPGBM lead candidate, using a patient- derived GBM CSC-based orthotopic intracranial tumor xenograft model. The results of the work being proposed will be significant, as they will serve to identify a drug development candidate for the treatment of GBM. Additionally, they will validate a novel druggable protein target for induced apoptosis and will identify a new mechanism for selective prodrug activation in GBM CSCs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	8/7/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $429,916 )
2023	2023	SCRIPPS RESEARCH INSTITUTE, THE	10550 NORTH TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	4/14/2023	NON-COMPETING CONTINUATION	$429,916
														Subtotal = $429,916

Issue Date FY: 2022 ( Subtotal = $528,172 )
2022	2022	SCRIPPS RESEARCH INSTITUTE, THE	10550 NORTH TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	6/15/2022	NON-COMPETING CONTINUATION	$528,172
														Subtotal = $528,172

Issue Date FY: 2021 ( Subtotal = $534,558 )
2021	2021	SCRIPPS RESEARCH INSTITUTE, THE	10550 NORTH TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	3/24/2021	NON-COMPETING CONTINUATION	$534,558
														Subtotal = $534,558

Issue Date FY: 2020 ( Subtotal = $544,136 )
2020	2020	SCRIPPS RESEARCH INSTITUTE, THE	10550 NORTH TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	3/25/2020	NON-COMPETING CONTINUATION	$544,136
														Subtotal = $544,136

Issue Date FY: 2019 ( Subtotal = $557,933 )
2019	2019	SCRIPPS RESEARCH INSTITUTE, THE	10550 NORTH TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	5/28/2019	NEW	$557,933
														Subtotal = $557,933

Grand Total All Awards = $2,594,715

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma

Award Number: R01NS112482

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2019

PERIOD OF PERFORMANCE END DATE: 03/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer